Effect of intravitreal bevacizumab injection for macular edema in retinal vein occlusion with respect to the type of RVO

1.Kayo Kure¹
2.Takashi Ueta¹
3.Aya Iriyama²
4.Yasuo Yanagi¹

¹The University of Tokyo Hospital, Tokyo, Japan
²Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan

Purpose: To examine the effect of intravitreal bevacizumab injection (IVB) with respect to the type of RVO that may influence the outcome.

Methods: We retrospectively evaluated 140 patients with RVO who were treated with IVB.

Results: Initial VA was LogMAR 0.69 and 1.30 in non-ischemic and ischemic CRVO, respectively. In major and macular BRVO, the initial VA was LogMAR 0.51 and 0.33, with no statistical difference between non-ischemic and ischemic type. In CRVO patients, mean visual acuity gain was logMAR 0.25 and 0.26 for non-ischemic type and ischemic type, respectively. In patients with major BRVO, mean VA gain was logMAR 0.36 and 0.34 for non-ischemic type and ischemic type, respectively. In patients with macular BRVO, mean VA gain was logMAR 0.31.

Conclusion: In our study, patients with macular BRVO seemed to benefit most from intravitreal bevacizumab injections.